Trial of Glycopyrronium versus Hyoscine to treat drooling in children - DRI Trial (Drooling Reduction Intervention)

ISRCTN ISRCTN75287237
DOI https://doi.org/10.1186/ISRCTN75287237
EudraCT/CTIS number 2013-000863-94
Secondary identifying numbers 14956
Submission date
22/07/2013
Registration date
22/07/2013
Last edited
15/02/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Mrs Joanne Morrison
Scientific

4th Floor William Leech Building
Framlington Place
Newcastle Upon Tyne
NE2 4HH
United Kingdom

Email joanne.morrison@newcastle.ac.uk

Study information

Study designRandomised interventional trial; Design type: Treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleA single blind study comparing the efficacy of Glycopyrronium and Hyoscine on drooling in children with neurodisability - DRI Trial (Drooling Reduction Intervention)
Study acronymDRI
Study objectivesDrooling is a common problem in children with neurodisabilities such as cerebral palsy or Down Syndrome. Drooling leads to the facial skin becoming sore, frequent changes of clothes, damage to educational equipment, and often social embarrassment for the child and family. There is no evidence about the relative effectiveness of the two medications most commonly used to reduce drooling.

This study aims to identify:
- whether Glycopyrronium or Hyoscine is more effective and at what dose
- side-effects of the medications and how these relate to dose

Over 9 months paediatricians, with special interest in neurodisability working in 15 UK centres, will recruit 90 children from outpatient clinics; these children will not have received any medication for drooling. Children will have a non-progressive neurodisability and be less that 16 years old. They will have no contraindications to the medications. Children will be randomised for treatment and medication will be increased, as tolerated for 4 weeks; this will be under the guidance of the Trial Research Paediatrician, working to the study protocol.

The Trial Outcome Assessor will collect outcome data before the intervention and then at 4, 12 and 52 weeks. Well established scales of the impact of the medication on family and child will be used. Children of sufficient age and ability (identified with help of local paediatrician and the family) will be asked for their own views in an interview.

The results will lead to guidance on: drug doses, intervals for increasing medication, and monitoring of adverse effects. The results have the potential to be adopted immediately because the medications are already in use and surveys of parents and professionals, before the study started, indicates that this trial is needed and the results anticipated with interest.

The overall study duration will be 2 years.
Ethics approval(s)13/NE/0078
Health condition(s) or problem(s) studiedTopic: Medicines for Children Research Network; Subtopic: All Diagnoses; Disease: All Diseases
InterventionPrimary Intervention, Commencement of Glycopyrronium oral medication or Hyoscine patch.
Secondary intervention, Adjustments to dosing of Glycopyrronium or Hyoscine.
Tertiary Intervention, Appointment to decide on ongoing treatment after 12 weeks.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Glycopyrronium, Hyoscine
Primary outcome measureDrooling Impact Scale score at 4 weeks
Secondary outcome measuresNot provided at time of registration
Overall study start date01/09/2013
Completion date30/09/2014

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit36 Months
Upper age limit16 Years
SexBoth
Target number of participantsPlanned Sample Size: 90; UK Sample Size: 90
Key inclusion criteria1. Treatment naive children, with nonprogressive neurodisability, who require Glycopyrronium or Hyoscine to reduce drooling
2. No contraindication to either medication
3. Age between 36 months and below 16 years; Target Gender: Male & Female
Key exclusion criteria1. Children who have received medical or surgical interventions for drooling
2. Children with medical conditions for which either medication is contraindicated
3. Children whose parents are considered unable to follow the study protocol
4. Parents without mobile or home telephone (required for communication with research registrar and assistant)
5. Parents whose use of English would not allow them to understand the issues in the 6. Consent form or be able to take part in the phone calls with the Trial Research Paediatrician and Trial Outcome Assessor
Date of first enrolment01/09/2013
Date of final enrolment30/09/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

4th Floor William Leech Building
Newcastle Upon Tyne
NE2 4HH
United Kingdom

Sponsor information

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre

New Victoria Wing
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
England
United Kingdom

Website http://www.newcastle-hospitals.org.uk/
ROR logo "ROR" https://ror.org/05p40t847

Funders

Funder type

Charity

Castang Foundation (UK)

No information available

Royal College of Paediatrics and Child Health (UK)
Private sector organisation / Associations and societies (private and public)
Alternative name(s)
RCPCH
Location
United Kingdom
WellChild Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 17/02/2014 Yes No
Results article results 01/04/2018 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

15/02/2018: Publication reference added.